Pharmaceutical Executive-07-01-2016

Pharm Exec convenes a roundtable discussion with several company chief information officers (CIOs) and IMS Health to explore ways to turn the vast reams of data now being generated in the transactional tsunami of modern healthcare into truly meaningful insights for its users.

Pharm Exec sits down with Habib Dable, a 22-year veteran of Bayer, to discuss his few first months at the helm of the company’s US pharma operations, where he is leading Bayer’s repositioning as a drug innovator and advancing its “all-in” approach to product partnering.

Amid today's growing constituency of cancer survivors, oncology is testing the historic divide in medicine between what’s science and what’s social.

A look at how Europe's new accelerated drug approval scheme can evolve existing review pathways for the better-and take a page from FDA

Pharm Exec adds up some interesting figures from recent industry news.

As drugmakers seek engagement, patients are buried in content. Thus, quality and appealing material is a must to grab a share of the narrow bandwidths that patients possess.

Time for new pharma strategies to combat deadly drug-resistant infections

The UK vote suddenly puts industry on a turbulent track in Europe. The many challenges and effects are outlined here.

With one of the oldest populations in the world, Italy faces a daunting question: how can it protect its universal healthcare system while maintaining the country’s high quality standards for public healthcare and ensuring its survival for the next generation? Up to the challenge, Italy must now learn to do more with less.

Click the title above to open the Pharmaceutical Executive July 2016 issue in an interactive PDF format.